Clinical Trial Update: Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating neoadjuvant Apatinib plus Paclitaxel in local advanced triple-negative breast cancer; status is currently UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Apatinib (apatinib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN